SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost‐effectiveness of additional blood screening tests in the Netherlands
9 references·12 citing·36 second hop
Cost‐effectiveness of additional blood screening tests in the Netherlands (2011)Cost‐effectiveness of additional blood sc…Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion (2009)Infectivity of human immunode…Emerging infectious disease agents and their potential threat to transfusion safety (2009)Emerging infectious disease a…The NICE Cost-Effectiveness Threshold (2008)The NICE Cost-Effectiveness T…Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Cost‐effectiveness of nucleic…The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations (2003)The cost‐effectiveness of NAT…Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Mathematic modeling of the ri…Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases (2000)Nucleic acid amplification te…Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis (1998)Screening for human T cell le…Cost‐effectiveness of expanded human immunodeficiency virus‐testing protocols for donated blood (1997)Cost‐effectiveness of expande…Modelling the risk of transfusion‐transmitted syphilis: a reconsideration of blood donation testing strategies (2018)Modelling the risk of transfu…Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis (2018)Assessing the value of screen…Testing for HTLV 1 and HTLV 2 among blood donors in Western Saudi Arabia: prevalence and cost considerations (2017)Testing for HTLV 1 and HTLV 2…Reconsideration of blood donation testing strategy for human T‐cell lymphotropic virus in Australia (2017)Reconsideration of blood dona…Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV , HCV and HBV (2017)Development of a web‐based ap…Donor blood screening and moral responsibility: how safe should blood be? (2016)Donor blood screening and mor…Cost effectiveness of adding nucleic acid testing to hepatitis B , hepatitis C , and human immunodeficiency virus screening of blood donations in Z imbabwe (2016)Cost effectiveness of adding …Blood donor selection in European Union directives: room for improvement. (2016)Blood donor selection in Euro…Blood donor deferral: time for change? An evidence-based analysis (2016)Blood donor deferral: time fo…Transfusion sanguine : en toute sécurité d’approvisionnement (2015)Transfusion sanguine : en tou…An inventory of concerns behind blood safety policies in five Western countries (2015)An inventory of concerns behi…Cost‐effectiveness of questionnaires in preventing transfusion‐transmitted infections (2013)Cost‐effectiveness of questio…The Risk of Transfusion-Transmitted Viral Infections (1996)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)NAT of the United States and Canadian blood supply (2000)Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century (2010)Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress (2010)Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations (2011)Recommendations for Reporting Cost-effectiveness Analyses (1996)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States (2004)Estimating the cost of blood: past, present, and future directions (2007)Clinical Decision Analysis (1980)The Markov Process in Medical Prognosis (1983)Preference-Based Measures in Economic Evaluation in Health Care (2000)Equity and the economic evaluation of healthcare (2001)A review and critique of modelling in prioritising and designing screening programmes (2007)Methods for the economic evaluation of health care programmes (1987)Perception of Risk (1987)Cost-Effectiveness in Health and Medicine (1996)Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus (2005)Lessons from Cost-Effectiveness Research for United States Public Health Policy (2007)Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision Making (2008)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (2010)Sensitivity and specificity of the Patient Health Questionnaire (PHQ-9, PHQ-8, PHQ-2) and General Anxiety Disorder scale (GAD-7, GAD-2) for depression and anxiety diagnosis: a cross-sectional study in a Peruvian hospital population (2023)Bullying in school: are short pupils at risk? Questionnaire study in a cohort (2000)False‐reactive microbiologic screening test results in Swedish blood donors—how big is the problem? A survey among blood centers and deferred donors (2006)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)The cost-effectiveness of digital health interventions: A systematic review of the literature (2022)Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing (2005)Assessing the impact of HBV NAT on window period reduction and residual risk (2006)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)Prevention of transfusion-transmitted infections (2019)
this work references cited by second hop

References

  • 2008The NICE Cost-Effectiveness Threshold868 cited
  • 2009Emerging infectious disease agents and their potential threat to transfusion safety427 cited
  • 2003The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations264 cited
  • 2009Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion221 cited
  • 2000Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases218 cited
  • 2004Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States136 cited
  • 1997Cost‐effectiveness of expanded human immunodeficiency virus‐testing protocols for donated blood130 cited
  • 2002Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT117 cited
  • 1998Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis41 cited

Cited by

  • 2018Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis140 cited
  • 2016Blood donor selection in European Union directives: room for improvement.33 cited
  • 2017Reconsideration of blood donation testing strategy for human T‐cell lymphotropic virus in Australia25 cited
  • 2018Modelling the risk of transfusion‐transmitted syphilis: a reconsideration of blood donation testing strategies

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

22 cited
  • 2013Cost‐effectiveness of questionnaires in preventing transfusion‐transmitted infections20 cited
  • 2016Cost effectiveness of adding nucleic acid testing to hepatitis B , hepatitis C , and human immunodeficiency virus screening of blood donations in Z imbabwe14 cited
  • 2017Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV , HCV and HBV14 cited
  • 2016Donor blood screening and moral responsibility: how safe should blood be?12 cited
  • 2015An inventory of concerns behind blood safety policies in five Western countries12 cited
  • 2016Blood donor deferral: time for change? An evidence-based analysis12 cited
  • 2017Testing for HTLV 1 and HTLV 2 among blood donors in Western Saudi Arabia: prevalence and cost considerations11 cited
  • 2015Transfusion sanguine : en toute sécurité d’approvisionnement8 cited